Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 6, Pages 1907
Publisher
MDPI AG
Online
2020-03-12
DOI
10.3390/ijms21061907
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials
- (2020) A. Mantovani et al. DIABETES & METABOLISM
- HOMA-IR is an independent predictor of advanced liver fibrosis in nondiabetic nonalcoholic fatty liver disease
- (2019) Hideki Fujii et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Plasma Fibroblast Growth Factor 21 is Associated with Severity of Nonalcoholic Steatohepatitis in Patients with Obesity and Type 2 Diabetes
- (2019) Diana Barb et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Sex Differences in NAFLD : State of the Art and Identification of Research Gaps
- (2019) Amedeo Lonardo et al. HEPATOLOGY
- PS-110-Ketohexokinase inhibitor PF-06835919 administered for 6 weeks reduces whole liver fat as measured by magnetic resonance imaging-proton density fat fraction in subjects with non-alcoholic fatty liver disease
- (2019) Roberto Calle et al. JOURNAL OF HEPATOLOGY
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice
- (2019) Daniel Lindén et al. Molecular Metabolism
- Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
- (2019) Philip Newsome et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial
- (2019) Fernando Bril et al. DIABETES CARE
- The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis
- (2019) Zobair M. Younossi et al. JOURNAL OF HEPATOLOGY
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the United States
- (2019) Zobair M. Younossi et al. DIABETES CARE
- Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study
- (2019) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design
- (2019) Quentin M. Anstee et al. Contemporary Clinical Trials
- 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETES CARE
- Co-administration of APD668, a G protein-coupled receptor 119 agonist and linagliptin, a DPPIV inhibitor, prevents progression of steatohepatitis in mice fed on a high trans-fat diet
- (2018) Umakant Ashok Bahirat et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management
- (2018) Michaël J.B. van Baar et al. DIABETES CARE
- Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
- (2018) Mohammad Shafi Kuchay et al. DIABETES CARE
- Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study
- (2018) Ronnie Aronson et al. DIABETES OBESITY & METABOLISM
- Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme
- (2018) K. Cusi et al. DIABETIC MEDICINE
- A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment
- (2018) Agostino Consoli et al. Expert Opinion On Drug Safety
- Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis
- (2018) Frank Tacke EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes
- (2018) Sean L. Zheng et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Hepatocellular carcinoma as a leading cause of cancer-related deaths in Japanese type 2 diabetes mellitus patients
- (2018) Toshihide Shima et al. JOURNAL OF GASTROENTEROLOGY
- Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study
- (2018) Gyuri Kim et al. JOURNAL OF HEPATOLOGY
- Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?
- (2018) Amedeo Lonardo et al. JOURNAL OF HEPATOLOGY
- MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
- (2018) Philip Ambery et al. LANCET
- Combination of APD668, a G protein-coupled receptor 119 agonist with linagliptin, a DPPIV inhibitor, prevents progression of steatohepatitis in a murine model of non-alcoholic steatohepatitis with diabetes
- (2018) Umakant Ashok Bahirat et al. Medical Molecular Morphology
- Clinical application of angiotensin receptor blockers in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis
- (2018) Yating Li et al. Oncotarget
- Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study
- (2018) Devin Abrahami et al. BMJ-British Medical Journal
- Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study
- (2018) Devin Abrahami et al. BMJ-British Medical Journal
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
- (2018) Richard E Pratley et al. Lancet Diabetes & Endocrinology
- Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
- (2018) Bernhard Ludvik et al. Lancet Diabetes & Endocrinology
- Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study
- (2018) Hisamitsu Ishihara et al. Diabetes Therapy
- Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study
- (2018) Hisamitsu Ishihara et al. Diabetes Therapy
- A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials
- (2018) Joachim Tillner et al. DIABETES OBESITY & METABOLISM
- Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial
- (2018) Naveed Sattar et al. DIABETOLOGIA
- Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial)
- (2018) Yoshio Sumida et al. HEPATOLOGY RESEARCH
- Sex differences in glucose and fatty acid metabolism in non-obese Asians
- (2018) Zhiling Chan et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Risk factors associated with nonalcohol fatty liver disease and fibrosis among patients with type 2 diabetes mellitus
- (2018) Hongli Zhao et al. MEDICINE
- Role of the PNPLA3 polymorphism rs738409 on silymarin + vitamin E response in subjects with non-alcoholic fatty liver disease
- (2018) Rocío Aller et al. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS
- PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver disease
- (2018) Jin-Zhi Wang et al. World Journal of Clinical Cases
- A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?
- (2018) Amedeo Lonardo et al. ACTA DIABETOLOGICA
- Vitamin E Improves Transplant-free Survival and Hepatic Decompensation among Patients with NASH and Advanced Fibrosis
- (2018) Eduardo Vilar-Gomez et al. HEPATOLOGY
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
- (2018) Arun Sanyal et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study
- (2018) Edgar D. Charles et al. Obesity
- Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study
- (2018) Devin Abrahami et al. BMJ-British Medical Journal
- Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
- (2018) Yuya Seko et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation
- (2017) David Goldberg et al. GASTROENTEROLOGY
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- A novel glucagon-like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice
- (2017) M. Pilar Valdecantos et al. HEPATOLOGY
- Insulin resistance increases the risk of incident type 2 diabetes mellitus in patients with non-alcoholic fatty liver disease
- (2017) Yuya Seko et al. HEPATOLOGY RESEARCH
- Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus
- (2017) Yoshio Sumida et al. HEPATOLOGY RESEARCH
- The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin
- (2017) Akihiko Takeda et al. INTERNAL MEDICINE
- Estimation of serum “true collagen type III formation” (Pro-C3) levels as a marker of non-alcoholic steatohepatitis in a prospective cohort
- (2017) D.J. Leeming et al. JOURNAL OF HEPATOLOGY
- Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus
- (2017) Wenjie Dai et al. MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
- (2017) Satish K. Garg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes
- (2017) Robert S. Busch et al. POSTGRADUATE MEDICINE
- Semaglutide, lipid-lowering drugs, and NAFLD
- (2017) Niki Katsiki et al. Lancet Diabetes & Endocrinology
- Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis
- (2017) Yasushi Honda et al. Scientific Reports
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
- (2016) Kenneth Cusi et al. ANNALS OF INTERNAL MEDICINE
- Understanding the Physiology of FGF21
- (2016) Ffolliott Martin Fisher et al. Annual Review of Physiology
- Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models
- (2016) Mi-Kyung Kim et al. ARCHIVES OF PHARMACAL RESEARCH
- GPR119: a promising target for nonalcoholic fatty liver disease
- (2016) Jin Won Yang et al. FASEB JOURNAL
- Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
- (2016) Zobair M. Younossi et al. HEPATOLOGY
- Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus
- (2016) Yuya Seko et al. HEPATOLOGY RESEARCH
- Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus
- (2016) Yuya Seko et al. HEPATOLOGY RESEARCH
- Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis
- (2016) Stefano Ballestri et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
- (2016) Juan P Frías et al. Lancet Diabetes & Endocrinology
- Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
- (2016) Chikara Komiya et al. PLoS One
- Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)
- (2015) Rohit Loomba et al. HEPATOLOGY
- Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus
- (2015) Hiromi Kan et al. HEPATOLOGY RESEARCH
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Imeglimin Normalizes Glucose Tolerance and Insulin Sensitivity and Improves Mitochondrial Function in Liver of a High-Fat, High-Sucrose Diet Mice Model
- (2015) Guillaume Vial et al. DIABETES
- Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
- (2014) Benjamin M. Scirica et al. CIRCULATION
- Can a Selective PPARγ Modulator Improve Glycemic Control in Patients With Type 2 Diabetes With Fewer Side Effects Compared With Pioglitazone?
- (2014) Alex M. DePaoli et al. DIABETES CARE
- Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the WELCOME* study
- (2014) Eleonora Scorletti et al. HEPATOLOGY
- Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)
- (2014) Yuichiro Eguchi et al. HEPATOLOGY RESEARCH
- Inventing new medicines: The FGF21 story
- (2014) Alexei Kharitonenkov et al. Molecular Metabolism
- The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes
- (2013) Gregory Gaich et al. Cell Metabolism
- Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients
- (2013) Takashi Nakahara et al. JOURNAL OF GASTROENTEROLOGY
- Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study
- (2012) Yuichiro Eguchi et al. JOURNAL OF GASTROENTEROLOGY
- Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis
- (2010) M. O. Rakoski et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Atorvastatin and Antioxidants for the Treatment of Nonalcoholic Fatty Liver Disease: The St Francis Heart Study Randomized Clinical Trial
- (2010) Temitope Foster et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease
- (2010) Manal F. Abdelmalek et al. HEPATOLOGY
- Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway
- (2010) Nitika Arora Gupta et al. HEPATOLOGY
- Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH
- (2010) Yuki Kimura et al. JOURNAL OF GASTROENTEROLOGY
- Statins Are Associated With a Reduced Risk of Hepatocellular Carcinoma in a Large Cohort of Patients With Diabetes
- (2009) Hashem B. El–Serag et al. GASTROENTEROLOGY
- A Pilot Study Using Simvastatin in the Treatment of Nonalcoholic Steatohepatitis
- (2009) Austin Nelson et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Pharmacological Interventions for Nonalcoholic Fatty Liver Disease in Adults and in Children: A Systematic Review
- (2009) Piotr Socha et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis
- (2008) Guruprasad P. Aithal et al. GASTROENTEROLOGY
- Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia
- (2008) Hideyuki Hyogo et al. METABOLISM-CLINICAL AND EXPERIMENTAL
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started